# MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus

> **NCT04810507** · PHASE4 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 89 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Anagliptin BID Treatment

## Key facts

- **NCT ID:** NCT04810507
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2020-09-02
- **Final completion:** 2021-01-05
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810507, "MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04810507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*